VRTX (STOCKS)
Vertex Pharmaceuticals Inc
$524.637500
-1.092500 (-0.21%)
Prev close: $525.730000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Reshma Kewalramani
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $146,152.01M
- Employees
- 6,100
- P/E (TTM)
- 30.59
- P/B (TTM)
- 6.58
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $12.59B |
| Benefits Costs and Expenses | $7.31B |
| Cost Of Revenue | $1.76B |
| Costs And Expenses | $7.81B |
| Gross Profit | $10.82B |
| Operating Expenses | $6.05B |
| Selling, General, and Administrative Expenses | $2.01B |
| Other Operating Expenses | $4.04B |
| Operating Income/Loss | $4.78B |
| Income/Loss From Continuing Operations After Tax | $4.41B |
| Income/Loss From Continuing Operations Before Tax | $5.27B |
| Income Tax Expense/Benefit | $869.30M |
| Net Income/Loss | $4.41B |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $4.41B |
| Net Income/Loss Available To Common Stockholders, Basic | $4.41B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $17.33 |
| Diluted Earnings Per Share | $17.17 |
| Basic Average Shares | 762,700,000 |
| Diluted Average Shares | 768,500,000 |
| Assets | $27.42B |
| Current Assets | $12.54B |
| Inventory | $1.77B |
| Other Current Assets | $10.78B |
| Noncurrent Assets | $14.88B |
| Intangible Assets | $412.80M |
| Other Non-current Assets | $14.47B |
| Liabilities | $7.18B |
| Current Liabilities | $3.94B |
| Accounts Payable | $429.50M |
| Other Current Liabilities | $3.51B |
| Noncurrent Liabilities | $3.24B |
| Equity | $20.25B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $20.25B |
| Liabilities And Equity | $27.42B |
| Net Cash Flow From Operating Activities | $4.29B |
| Net Cash Flow From Operating Activities, Continuing | $4.29B |
| Net Cash Flow From Investing Activities | -$882.80M |
| Net Cash Flow From Investing Activities, Continuing | -$882.80M |
| Net Cash Flow From Financing Activities | -$2.20B |
| Net Cash Flow From Financing Activities, Continuing | -$2.20B |
| Exchange Gains/Losses | -$40.80M |
| Net Cash Flow | $1.17B |
| Net Cash Flow, Continuing | $1.21B |
| Comprehensive Income/Loss | $4.55B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $4.55B |
| Other Comprehensive Income/Loss | $4.55B |
| Other Comprehensive Income/Loss Attributable To Parent | $149.60M |